News

The Association for the Accreditation of Human Research Protection Programs has announced the accreditation of nine research organizations in the U.S., Belgium, China and Taiwan.

WIRB has launched a new tool designed to assist participating institutions in complying with NIH’s new single review policy for multi-site clinical trials.

The second in our three-part series, Improving efficiencies and sponsor/CRO collaboration through advanced CTMS, explores how technology can foster better collaboration.

Cloud-based clinical analytics and software solutions provider, Algorics, has announced the newest release of its risk-based monitoring platform Acuity.

Women are often underrepresented in HIV clinical trials, but they appear to prefer finding out about trials by means of peer-to-peer communication, according to new analysis.

OmniComm Systems and Netherlands-based development company, the Centre for Human Drug Research (CHDR), have announced a collaboration.

With the inherent limitations of traditional data sources, this overview explores the definitions and strategic fundamentals that inform machine learning and modeling techniques.

CluePoints announced the addition of Patient Profile reports to its Risk-Based Monitoring and Data Quality Oversight solution.

An emergency summit to discuss how to safeguard the clinical research industry in the U.K. before and after Brexit will take place on April 5.

The first in this 3-part series, Improving efficiencies and sponsor/CRO collaboration through advanced CTMS, reveals the quickest way that sponsors and CROs can save money and thus keep trials affordable and efficient.

Updated employee announcements, business news, awards and recognition in the industry today.

A recently completed study reported that the 505(b)(2) approval pathway for new drug applications in the US has not led to shorter approval times.

Almac Diagnostics has announced its selection by the EORTC as a partner for the molecular profiling of cancer patient samples.

CROS NT has announced the acquisition of the clinical division of PM Clinical Limited.

The expanding role of incentives is a healthy trend in an industry defined by high costs and the pressure of deadlines, and such agreements have evolved recently to benefit all involved.

A recently released study regarding off-label prescribing in Europe has caused confusion as it lacked clarity on how the issue of how to govern off-label use going forward.

The economics and power of the cloud will drive its increasing adoption by pharma organizations for the foreseeable future as research becomes more data-intensive.

Regulators in the European Union (EU) and the U.S. have agreed to recognize inspections of manufacturing sites for human medicines conducted in their respective territories on both sides of the Atlantic.

Frost & Sullivan have released a whitepaper, with Asia Pacific specialist CRO Novotech, revealing that Asia is becoming an ideal destination for clinical trials.

The European Union, looking to re-invent itself in the wake of Brexit, is considering withdrawing policy in the field of public health.